Aptose Biosciences Inc., a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, has entered into a license agreement with CrystalGenomics, Inc. for China rights to CG-806 (including People’s Republic of China, Hong Kong and Macau). Aptose will now own worldwide rights (excluding Korea) to develop and commercialize CG-806, a first-in-class, highly potent oral small molecule being developed for acute myeloid leukemia (AML), B-cell malignancies and other hematologic malignancies.

Under the agreement, CrystalGenomics will receive an upfront payment of $3 million and is eligible for development, regulatory and commercial-based milestones, as well as single-digit royalties on product sales in China. Total deal value for the China territory, including the upfront payment, is up to $125 million.

Recently Aptose exercised its option to obtain the exclusive license from CrystalGenomics to develop and commercialize CG-806 worldwide outside of China and  Korea.  This new agreement extends that license agreement to include China.